Drugs / ACP-319
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02157324 | Aug 2014 → Jul 2020 overdue | B-cell chronic lymphocytic leukemia | Acerta Pharma BV | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02328014 | Dec 2014 → Jun 2020 | non-Hodgkin lymphoma, plasma cell myeloma | Acerta Pharma BV | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACP-319 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02157324 ↗ |